The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome

Pérez de Llano, Luis|||0000-0003-2652-6847; Dacal Rivas, David|||0000-0002-8203-0726; Malanda, Nuria Marina; Plaza, Vicente|||0000-0003-2567-5496; Gullón, José Antonio|||0000-0002-3007-0873; Muñoz-Esquerre, Mariana|||0000-0002-6747-7116; García-Moguel, Ismael|||0000-0002-2052-996X; Díaz Campos, Rocío Magdalena; Martínez-Moragón, Eva|||0000-0001-8986-9463; Harbenau Mena, Alicia; Cosio, Borja G|||0000-0002-6388-8209; Padilla, Alicia|||0000-0003-4625-2716; Cisneros, Carolina|||0000-0003-4297-4199

The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome

Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) tre...

Descripción completa

Detalles Bibliográficos
Autores:	Pérez de Llano, Luis\|\|\|0000-0003-2652-6847, Dacal Rivas, David\|\|\|0000-0002-8203-0726, Malanda, Nuria Marina, Plaza, Vicente\|\|\|0000-0003-2567-5496, Gullón, José Antonio\|\|\|0000-0002-3007-0873, Muñoz-Esquerre, Mariana\|\|\|0000-0002-6747-7116, García-Moguel, Ismael\|\|\|0000-0002-2052-996X, Díaz Campos, Rocío Magdalena, Martínez-Moragón, Eva\|\|\|0000-0001-8986-9463, Harbenau Mena, Alicia, Cosio, Borja G\|\|\|0000-0002-6388-8209, Padilla, Alicia\|\|\|0000-0003-4625-2716, Cisneros, Carolina\|\|\|0000-0003-4297-4199
Tipo de recurso:	artículo
Fecha de publicación:	2022
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:277690
Acceso en línea:	https://ddd.uab.cat/record/277690 https://dx.doi.org/urn:doi:10.2147/JAA.S338467
Access Level:	acceso abierto
Palabra clave:	Asthma Asthma-COPD overlap COPD

id	ES_bb2e162ff64e23efb6d6335890478cd5
oai_identifier_str	oai:ddd.uab.cat:277690
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap SyndromePérez de Llano, Luis\|\|\|0000-0003-2652-6847Dacal Rivas, David\|\|\|0000-0002-8203-0726Malanda, Nuria MarinaPlaza, Vicente\|\|\|0000-0003-2567-5496Gullón, José Antonio\|\|\|0000-0002-3007-0873Muñoz-Esquerre, Mariana\|\|\|0000-0002-6747-7116García-Moguel, Ismael\|\|\|0000-0002-2052-996XDíaz Campos, Rocío MagdalenaMartínez-Moragón, Eva\|\|\|0000-0001-8986-9463Harbenau Mena, AliciaCosio, Borja G\|\|\|0000-0002-6388-8209Padilla, Alicia\|\|\|0000-0003-4625-2716Cisneros, Carolina\|\|\|0000-0003-4297-4199AsthmaAsthma-COPD overlapCOPDAlthough biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months. Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with ≥1 exacerbation and ≥1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of "controlled" patients (with no exacerbations, no need for corticosteroids and ACT ≥ 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients. 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/277690https://dx.doi.org/urn:doi:10.2147/JAA.S338467reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2776902026-06-06T12:50:31Z
dc.title.none.fl_str_mv	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
spellingShingle	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome Pérez de Llano, Luis\|\|\|0000-0003-2652-6847 Asthma Asthma-COPD overlap COPD
title_short	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title_full	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title_fullStr	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title_full_unstemmed	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title_sort	The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
dc.creator.none.fl_str_mv	Pérez de Llano, Luis\|\|\|0000-0003-2652-6847 Dacal Rivas, David\|\|\|0000-0002-8203-0726 Malanda, Nuria Marina Plaza, Vicente\|\|\|0000-0003-2567-5496 Gullón, José Antonio\|\|\|0000-0002-3007-0873 Muñoz-Esquerre, Mariana\|\|\|0000-0002-6747-7116 García-Moguel, Ismael\|\|\|0000-0002-2052-996X Díaz Campos, Rocío Magdalena Martínez-Moragón, Eva\|\|\|0000-0001-8986-9463 Harbenau Mena, Alicia Cosio, Borja G\|\|\|0000-0002-6388-8209 Padilla, Alicia\|\|\|0000-0003-4625-2716 Cisneros, Carolina\|\|\|0000-0003-4297-4199
author	Pérez de Llano, Luis\|\|\|0000-0003-2652-6847
author_facet	Pérez de Llano, Luis\|\|\|0000-0003-2652-6847 Dacal Rivas, David\|\|\|0000-0002-8203-0726 Malanda, Nuria Marina Plaza, Vicente\|\|\|0000-0003-2567-5496 Gullón, José Antonio\|\|\|0000-0002-3007-0873 Muñoz-Esquerre, Mariana\|\|\|0000-0002-6747-7116 García-Moguel, Ismael\|\|\|0000-0002-2052-996X Díaz Campos, Rocío Magdalena Martínez-Moragón, Eva\|\|\|0000-0001-8986-9463 Harbenau Mena, Alicia Cosio, Borja G\|\|\|0000-0002-6388-8209 Padilla, Alicia\|\|\|0000-0003-4625-2716 Cisneros, Carolina\|\|\|0000-0003-4297-4199
author_role	author
author2	Dacal Rivas, David\|\|\|0000-0002-8203-0726 Malanda, Nuria Marina Plaza, Vicente\|\|\|0000-0003-2567-5496 Gullón, José Antonio\|\|\|0000-0002-3007-0873 Muñoz-Esquerre, Mariana\|\|\|0000-0002-6747-7116 García-Moguel, Ismael\|\|\|0000-0002-2052-996X Díaz Campos, Rocío Magdalena Martínez-Moragón, Eva\|\|\|0000-0001-8986-9463 Harbenau Mena, Alicia Cosio, Borja G\|\|\|0000-0002-6388-8209 Padilla, Alicia\|\|\|0000-0003-4625-2716 Cisneros, Carolina\|\|\|0000-0003-4297-4199
author2_role	author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Asthma Asthma-COPD overlap COPD
topic	Asthma Asthma-COPD overlap COPD
description	Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months. Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with ≥1 exacerbation and ≥1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of "controlled" patients (with no exacerbations, no need for corticosteroids and ACT ≥ 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients.
publishDate	2022
dc.date.none.fl_str_mv	2 2022-01-01 2022 2022-01-01
dc.type.none.fl_str_mv	Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/277690 https://dx.doi.org/urn:doi:10.2147/JAA.S338467
url	https://ddd.uab.cat/record/277690 https://dx.doi.org/urn:doi:10.2147/JAA.S338467
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869418003016187904
score	15,300724

The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome

Similares en LA Referencia